Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere's Q4 Loss Rises on Higher Expenses

NEW YORK (GenomeWeb News) – Nanosphere reported after the market closed Thursday that its fourth-quarter revenues dipped slightly while its net loss jumped 56 percent on higher SG&A costs.
 
The Northbrook, Ill.-based molecular diagnostics firm, which went public through an IPO in early November, said that its revenues for the three-month period ended Dec. 31 were $188,186 compared to $203,345 in the fourth quarter of 2006. Most of its revenues were from grants and government contracts.
 
The company’s net loss increased to $11.7 million, or $.84 per share, from $7.5 million, or $8.08 per share, a year ago, when it was a privately held company.
 
Nanosphere’s R&D spending was relatively flat at $5.5 million versus $5.4 million in the comparable period of 2006, while its SG&A costs nearly tripled to $3.8 million from $1.3 million. The firm has been building up its sales and marketing force to support initial sales of its Verigene System and molecular diagnostic assays.
 
The company’s Verigene platform, a hyper-coagulation panel that runs on the system, and a warfarin metabolism test were all cleared for US marketing by the Food and Drug Administration during the third quarter of 2007.
 
For full-year 2007, Nanosphere had revenues of $1.2 million, up from $1.1 million in 2006. Its net loss increased to $59.2 million, or $14.16 per share, from $45.7 million, or $52.78 per share, year over year.
 
Nanosphere’s 2007 R&D spending was $21.4 million versus $17.4 million in 2006, while its SG&A costs rose to $13.4 million from $5.4 million.
 
The firm finished the year with $114.3 million in cash.
 

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.